Intellectual Property
Jun. 18, 2011
Regulators Push Against Drug Settlements
Despite several setbacks, the Federal Trade Commission continues its crusade against patent settlements that it says violate antitrust laws when pharmaceutical companies pay competitors to delay sales of low-cost generic drugs.
Daily Journal Staff Writer
Despite setback after legal setback, the Federal Trade Commission continues its crusade against drug patent settlements in which pharmaceutical companies pay competitors to delay sales of low-cost generic medicines.
The FTC hasn't dismissed the idea of using its rule-making power to end so-called "pay-for-delay" agreements, which it contends violate antitrust laws. But the regulator is ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In